Treatment of Aspirin Exacerbated Respiratory Disease with a Low Salicylate Diet: A Pilot Crossover Study.

Related Articles

Treatment of Aspirin Exacerbated Respiratory Disease with a Low Salicylate Diet: A Pilot Crossover Study.

Otolaryngol Head Neck Surg. 2014 Oct 24;

Authors: Sommer DD, Hoffbauer S, Au M, Sowerby LJ, Gupta MK, Nayan S

Abstract
OBJECTIVE: Aspirin exacerbated respiratory disease (AERD) is comprised of aspirin/acetylsalicylic acid (ASA) sensitivity, bronchial asthma, and nasal polyposis. Treatment of this condition is challenging and may include topical/systemic steroids, endoscopic sinus surgery, and/or aspirin desensitization.
STUDY DESIGN: A prospective crossover pilot study (n = 10) was conducted in which patients were randomized into either of 2 groups with 6 weeks of regular diet (R) or 6 weeks of a low salicylate diet (LS).
SETTING: The study was conducted in a tertiary otolaryngology clinic.
SUBJECTS: Patients with AERD were enrolled in the study.
METHODS: Subjective (Sino-nasal Outcome Test-22 [SNOT-22], Nasal Sinus Symptom Scale [NSSS], and the Asthma Control Questionnaire-7 [ACQ-7]) and objective outcome instruments (Peri-Operative Sinus Evaluation [POSE] and Lund-Kennedy Endoscopic Score [LKES]) were used to evaluate patients at baseline, 6 weeks (at crossover), and 12 weeks.
RESULTS: Wilcoxon rank sum tests demonstrated that patients on the low salicylate diet had improved scores compared to their regular diet when evaluated by 4 of the 5 outcome measures (SNOT-22 pLS = 0.0059, NSSS pLS = 0.0195, LKES pLS = 0.0039, POSE pLS = 0.005).
CONCLUSION: Results of the pilot study indicate that implementation of a low salicylate diet improves the nasal symptoms and nasal endoscopy findings of individuals with AERD. Further research is required to support these findings.

PMID: 25344589 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Budesonide Inhalation Aerosol (PT008) Dose 1;   Drug: Budesonide Inhalation Aerosol (PT008) Dose 2;   Drug: Budesonide Inhalation Aerosol (PT008) Dose 3;   Drug: Budesonide Inhalation Aerosol (PT008) Dose 4;   Drug: Placebo
Sponsor:   Pearl Therapeutics, Inc.
Not yet recruiting – verified April 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Indacaterol 27.5 mcg;   Drug: Indacaterol 37.5;   Drug: Indacaterol 55 mcg;   Drug: Indacaterol 75 mcg;   Drug: Indacaterol 150 mcg;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting – verified October 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Placebo;   Drug: Tiotropium 5 µg q.d.;   Drug: Tiotropium 2.5 µg b.i.d.
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days